Abstract
Amyloid pathology in cognitively normal older adults has been associated with low memory performance and cognitive complaints, but findings are conflicting. Using a monozygotic twin design, we further explored this relation. We investigated 199 cognitively normal older adults (96 twin pairs) and assessed cognitive performance, cognitive complaints, and amyloid pathology on positron emission tomography and in the cerebrospinal fluid (CSF). Participants were on average 70.5 (SD = 7.6) years and 114 (57%) were female. Amyloid–positron emission tomography abnormality on visual read and lower CSF amyloid-β 1-42/1-40 ratio were associated with lower Rey visuospatial memory performance (respectively, β = −0.39 [SE = 0.17], p = 0.02 and β = 0.15 [SE = 0.07], p = 0.04). Twin analyses showed that CSF amyloid-β 1-42/1-40 ratio in one twin of a pair could predict visuospatial memory performance in the cotwin (r = 0.20 [SE = 0.10], p = 0.04). Monozygotic twin discordance analyses further showed a probable effect of disease staging on face-name associative memory performance. Our results suggest amyloid aggregation to be associated with lower visuospatial and face-name–associated memory performance in cognitively normal older adults, supporting the view that amyloid pathology leads to memory dysfunction in very early stages of the disease.
Original language | English |
---|---|
Pages (from-to) | 58-65 |
Number of pages | 8 |
Journal | Neurobiology of Aging |
Volume | 77 |
Early online date | 21 Jan 2019 |
DOIs | |
Publication status | Published - May 2019 |
Funding
EK, MK, AB, JT, MY, SDM, AAL, DLB, PS, PJV report no competing interests. CT has functioned in advisory boards of Fujirebio and Roche, received nonfinancial support in the form of research consumables from ADx Neurosciences and Euroimmun, and performed contract research or received grants from Janssen prevention center, Boehringer, Brainsonline, Axon Neurosciences, EIP Pharma, Roche. BNMvB is a trainer for the visual interpretation of [ 18 F]flutemetamol PET scans. He does not receive personal compensation for this. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant No. 115372 ). The authors thank all participating twins for their dedication to this study. This work also received in kind sponsoring of the CANTAB device from Cambridge Cognition, the CSF assay from ADx NeuroSciences/Euroimmun, and the PET-tracer [ 18 F]flutemetamol from GE Healthcare. Appendix A
Funders | Funder number |
---|---|
ADx Neurosciences and Euroimmun | |
EMIF | |
Fujirebio and Roche | |
Janssen Biotech | |
Innovative Medicines Initiative | 115372 |
Keywords
- Amyloid aggregation
- Cognitive complaints
- Memory performance
- Monozygotic twins
Cohort Studies
- Netherlands Twin Register (NTR)